# US 2014/0234275 A1 · Method for treating als via the increased production of factor h

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0234275 A1
- Document ID: US20140234275A1
- Status: Published application
- Kind: A1
- Application number: 14/181,405
- Filed: 2014-02-14
- Published: 2014-08-21
- Earliest claimed: 2013-02-15
- Inventors: Jason Williams
- Web page: https://patentgrep.com/patent/US20140234275A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 38/1709: {from mammals}
- A61K 38/1725: {Complement proteins, e.g. anaphylatoxin, C3a or C5a}
- A61K 38/30: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2 {(insulin-like growth factor binding protein A61K38/1754)}
- A61K 38/51: Lyases (4)
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 5/0667: {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells}
- C12N 15/86: Viral vectors
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2501/70: Enzymes
- C12N 2510/00: Genetically modified cells
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12Y 402/01002: Fumarate hydratase (4.2.1.2)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Methods and systems for the treatment for ALS incorporating stem cells harvested from the subject to be treated. These stem cells may be genetically altered with the addition of several genes of interest. Then, the patient will receive systemic gene therapy for the muscles and directed specifically at motor neurons. In this multi-pronged treatment approach, the stem cells provide immune regulation and the regeneration of motor neurons. And, the new motor neurons carry the added genes, which are protective against motor neuron death from ALS. The systemic therapy increases the amount of genes, which further reduces the effects of ALS. Additional gene therapy administered in the muscle will be further protective of the axon, while maintaining muscle mass and function.

## Claims

### Claim 1

A method of increasing the presence of Factor H in a mammalian subject, comprising:
a) harvesting adipose tissue from the subject;
b) purifying stem cells from the adipose tissue;
c) treating the stem cells with a compound that increases secretion of Factor H, optionally Selegeline; and
d) introducing the treated stem cells into the subject.

### Claim 2 (depends on 1)

The method according to claim 1, where the increased factor H secretion results in complement inhibition.

### Claim 3

A method of treating a motor neuron disease comprising:
a) harvesting stem cells from a patient with the motor neuron disease;
b) genetically altering the stem cells by the addition of one or more genes selected from the group consisting of IGF-1, TDP-42, and factor H;
c) administering the genetically altered stem cells systemically to the patient;
wherein the systemic administration serves to carry added genes which are protective against motor neuron death, and which further increases the amount of selective genes which further reduce the effects of motor neuron disease; and
d) optionally administering additional selected gene therapy components intramuscularly, wherein the IM administration serves to protect the axon and assist with maintaining muscle mass and function.
